#France #Guerbet #Villepinte #Lipiodol #Vascular Embolization

Guerbet's New Vascular Embolization Indication

Guerbet, a leader in the field of medical imaging, has recently marked a pivotal achievement concerning its product Lipiodol® Ultra Fluid. This milestone aims to expand the use of this iodinated ethyl ester of fatty acids, derived from poppy seed oil, specifically for vascular embolization applications. The announcement was made via a press release on April 24, 2026, and underscores the importance of collaboration among various EU member countries during the approval process.

The Significance of the Approval

The newly approved indication for Lipiodol® Ultra Fluid in interventional radiology signifies a step forward in treating patients with peripheral and central vascular embolizations utilizing cyanoacrylate-based surgical adhesives. The compatibility of Lipiodol® with these adhesives enhances the visualization quality of the procedures and allows for precise control over the polymerization time. The approval underscores the clinical relevance of Lipiodol®, especially for minimally invasive procedures.

Francois Convenant, Senior Vice President of Interventional Radiology at Guerbet, commented on the achievement, stating, "The approval of Lipiodol® for vascular embolization is a remarkable milestone for our field. Its X-ray visibility and unique physicochemical properties allow for more controlled, predictable, and safer embolization procedures. This indication formalizes years of clinical practice and paves the way for harmonizing tissue adhesive embolization techniques throughout Europe."

Clinical Implications and Benefits

The interventional radiology field is increasingly focused on embolic agents that offer precision, speed, and durability. As a liquid embolic agent, Lipiodol® combined with cyanoacrylate adhesives offers numerous advantages:

• - Real-time visualization during injection allows for immediate confirmation of blood vessel occlusion.
• - Adjustable viscosity and polymerization time enable customization of embolization strategies tailored to both proximal and distal vessels.
• - Effective and durable occlusion lessens the necessity for repeat interventions, which ultimately benefits patients and healthcare systems alike.

Supporting Healthcare Professionals

Guerbet emphasizes its commitment to backing interventional radiology professionals by offering:

• - Comprehensive scientific and clinical support.
• - Specialized medical training programs.
• - Increased on-site presence.
• - Reliable solutions that enhance patient care and are cost-effective for medical facilities.

About Guerbet

At Guerbet, our mission is to foster lasting relationships that improve quality of life for patients globally. As a pioneering global leader in medical imaging, we provide a diversified range of pharmaceutical products, medical devices, and digital solutions for diagnostic and interventional imaging. With over a century of experience in contrast agents, we employ 2,746 professionals worldwide and invest 10% of our revenue in research and development across our innovation centers in France and the USA. In 2025, Guerbet reported a revenue of €786 million and continues to drive innovation in the healthcare industry.

For more information about Guerbet, visit www.guerbet.com.